---
document_datetime: 2026-01-19 17:23:23
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/abiraterone-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: abiraterone-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2718112
conversion_datetime: 2026-01-20 20:08:35.638389
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Abiraterone Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 19/01/2026                          |                                             | Labelling and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000319650   | Update of the package leaflet with revised contact details of local representative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4. Additionally, the MAH took the opportunity to update the labelling and package leaflet text to align with the current approved mock-ups.   | PL   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|